Overview

Interferon α for the Therapy of Minimal Residual Disease

Status:
Unknown status
Trial end date:
2021-06-01
Target enrollment:
0
Participant gender:
All
Summary
This study aimed to evaluate the efficacy of interferon α among patients undergone unmanipulated blood and marrow transplantation following day 60 post-transplantation who were minimal residual disease positive after transplantation. Hematopoietic stem cell transplantation (HSCT) is an effective treatment option for acute leukemia and many other hematological malignancies. However, post-transplant relapse can occur in some patients, and the prognosis of these patients is usually very poor.The persistence or recurrence of minimal residual disease (MRD) in the post-transplant period is an independent risk factor of relapse. Therefore, MRD monitoring can be used to screen patients with a high risk of relapse to provide timely intervention and prevent post-transplant relapse.Interferon α-2b exerts a relatively strong immunomodulatory effect. It can kill acute leukemia (AL) cells by regulating T-cell and/or natural killer cell functions.Consequently, interferon α-2b may have potential therapeutic value for AL patients with MRD-positive after transplantation. The study hypothesis: Prevention of relapse using interferon α-2b following hematopoietic stem cell transplantation in patients with standard risk acute leukemia can reduce relapse rate.
Phase:
N/A
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Peking University People's Hospital
Treatments:
Interferon alpha-2
Interferon-alpha
Interferons
Criteria
Inclusion Criteria:

- Patients who had standard-risk acute myeloid leukemia(CR1 or CR2) had minimal residual
disease positive after hematopoietic stem cell transplantation

Exclusion Criteria:

- Patients with t(9;22)(q34; q11), t(15;17), inv(16)(p13q22), t(16;16)(p13; q22), or
t(8;21)(q22; q22) cytogenetic abnormalities;active graft-versus-host disease; active
infection; organ failure; exposure to donor lymphocyte infusion prior to enrollment